BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. External Web Site Icon Friedlaender Alex et al. Breast cancer research and treatment 2019 Jan

Specific PHGKB|Cancer|PHGKB

Breast Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Feb 07, 2019

---

• BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.  
  Friedlaender Alex et al. Breast cancer research and treatment 2019 Jan
• Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.  
  Bhaskaran Shanmuga Priya et al. International journal of cancer 2019 Jan
• Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-positive Breast Cancer Patients.  
  Kim Ji-Yeon et al. International journal of cancer 2019 Feb
• The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.  
  Olsson-Brown Anna et al. Breast (Edinburgh, Scotland) 2019 Jan 4494-100
• Application of circulation tumor cells detection in diagnosis and treatment of breast tumors.  
  Cen Chunmei et al. Rejuvenation research 2019 Feb
• ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T 1-2 N 1 M 0 ER-Positive HER2-Negative Breast Cancer.  
  Wang Maoli et al. Annals of surgical oncology 2019 Jan
• BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.  
  Mehemmai Chiraz et al. Pathology oncology research : POR 2019 Feb
• Cancer Target Gene Screening: a web application for breast cancer target gene screening using multi-omics data analysis.  
  Kim Hyung-Yong et al. Briefings in bioinformatics 2019 Jan
• Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).  
  Condorelli R et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 Jan
• Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma.  
  Song Guiqin et al. The Journal of international medical research 2019 Feb 300060518815364